Ivermectin is a well-known anti-parasite drug, cheap to make and proven to be safe, that a lot of physicians think is effective against Covid-19.
Several states in India tried it out. New Covid-19 cases dropped dramatically.
The reaction of India’s public health agency? Astonishingly, following the guidance of the World Health Organization, they dropped invermectin from a list of recommended treatments.
Physicians in India are still free to prescribe invermectin, but the only treatments with the official seal of approval are the expensive vaccines made by major drug companies, all still in short supply in India.
I don’t see how this decision benefits anyone except the drug companies themselves.
Nick Corbishley, posting on the Naked Capitalism blog, tells the story:
India’s Directorate General of Health Services (DGHS) has executed a policy reversal that could have massive implications for the battle against covid-19, not only in India but around the world. Hundreds of thousands, if not millions of lives, are at providing stake.
Providing no explanation whatsoever, the DGHS has overhauled its COVID-19 treatment guidelines and removed almost all of the repurposed medicines it had previously recommended for treating asymptomatic and mild cases.
They include the antibiotic doxycycline, hydroxychloroquine zinc, ivermectin and even multivitamins. The only medicines that are still recommended for early treatment are cold medicines, antipyretics such as paracetamol and inhaled budesonide.
“No other covid-specific medication [is] required,” say the new guidelines, which also discourage practitioners from prescribing unnecessary tests such as CT scans. [snip]
The decision to remove ivermectin, multivitamins and zinc from the treatment guidelines is hard to comprehend given the current state of play in India — unless one assumes foul play.
After suffering one of the worst covid-19 outbreaks since the pandemic began, resulting in the loss of hundreds of thousands of lives, India is not just flattening the curve, it is crushing it.
And the widespread use of ivermectin, a potent anti-viral and anti-inflammatory with an excellent safety profile, appears to have played an instrumental role. [snip]
Other countries in the region have already taken notice. Indonesia just approved the use of ivermectin in Kudus, a local contagion hotspot.
This is the last thing the World Health Organization (WHO) and the pharmaceutical companies whose interests it broadly represents want.
As such, it was no surprise that WHO was delighted with the DGHS’ policy reversal. “Evidence based guidelines from @mohfw DGHS – simple, rational and clear guidance for physicians,” tweeted WHO’s chief scientist Soumya Swaminathan, of Indian descent. “Should be translated and disseminated in all Indian languages.” [snip]
It’s worth noting that while India’s DGHS has dumped most cheap off-patent treatment options against Covid, including even multivitamins, more expensive patented medicines continue to get the green light.
They include Gilead’s prohibitively expensive antiviral Remdesivir, which DGHS continues to recommend for “select moderate/ severe hospitalized COVID-19 patients,” even though “it is only an experimental drug with potential to harm.” It has also authoriszed the use of the anti-inflammatory medicine tocilizumab, which costs hundreds of dollars a dose.
Source: Naked Capitalism.